Amgen
AMGN
NZ$480.99
Share price
0.30%
Change (1 day)
-3.53%
Change (1 year)
Categories
The biotechnology company Amgen was founded in 1980 as AMGen. With approximately 20,000 employees, Amgen is one of the world's largest biotechnology companies with annual sales of approximately $ 24 billion in 2018.
Amgen (AMGN) - Cash on Hand
Cash on Hand as of March 2025 : NZ$14.55 Billion
According to Amgen's latest financial reports the company has NZ$14.55 Billion in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Amgen - Cash on Hand chart (from 1996 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | NZ$21.22 B | 22.68% |
| 2023-12-31 | NZ$17.30 B | 18.08% |
| 2022-12-31 | NZ$14.65 B | 24.56% |
| 2021-12-31 | NZ$11.76 B | -20.26% |
| 2020-12-31 | NZ$14.75 B | 11.52% |
| 2019-12-31 | NZ$13.23 B | -69.71% |
| 2018-12-31 | NZ$43.68 B | -25.56% |
| 2017-12-31 | NZ$58.68 B | 6.74% |
| 2016-12-31 | NZ$54.98 B | 19.91% |
| 2015-12-31 | NZ$45.85 B | 32.93% |
| 2014-12-31 | NZ$34.49 B | 46.1% |
| 2013-12-31 | NZ$23.60 B | -19.28% |
| 2012-12-31 | NZ$29.24 B | 10.59% |
| 2011-12-31 | NZ$26.44 B | 17.11% |
| 2010-12-31 | NZ$22.58 B | 22.02% |
| 2009-12-31 | NZ$18.50 B | 12.44% |
| 2008-12-31 | NZ$16.46 B | 76.31% |
| 2007-12-31 | NZ$9.33 B | 4.78% |
| 2006-12-31 | NZ$8.90 B | 15.89% |
| 2005-12-31 | NZ$7.68 B | -5.54% |
| 2004-12-31 | NZ$8.13 B | 3.28% |
| 2003-12-31 | NZ$7.88 B | -11.57% |
| 2002-12-31 | NZ$8.91 B | 39.01% |
| 2001-12-31 | NZ$6.41 B | 40.09% |
| 2000-12-31 | NZ$4.57 B | 79.42% |
| 1999-12-31 | NZ$2.55 B | 568.44% |
| 1998-12-31 | NZ$0.38 B | -7.39% |
| 1997-12-31 | NZ$0.41 B | 71.94% |
| 1996-12-31 | NZ$0.23 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | NZ$28.60 B | 96.55% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | NZ$19.46 B | 33.73% | 🇺🇸 USA |
 GlaxoSmithKline GSK | NZ$9.58 B | -34.13% | 🇬🇧 UK |
 Gilead Sciences GILD | NZ$13.09 B | -10.03% | 🇺🇸 USA |
 Biogen BIIB | NZ$4.29 B | -70.51% | 🇺🇸 USA |
 AbbVie ABBV | NZ$8.54 B | -41.25% | 🇺🇸 USA |
 Johnson & Johnson JNJ | NZ$64.05 B | 340.19% | 🇺🇸 USA |
 Illumina ILMN | NZ$2.04 B | -85.96% | 🇺🇸 USA |
 Eli Lilly LLY | NZ$5.31 B | -63.44% | 🇺🇸 USA |